At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 52 enrolled
Drug / intervention
dapagliflozin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin
In Brief
A Phase 4 clinical trial evaluating dapagliflozin and Placebo for Type 2 Diabetes. Completed, enrolled 52 participants across 1 site.
Detailed Summary
This is a single center, prospective, randomized, placebo -controlled, parallel design and double blind study to evaluate oxidative stress, inflammation and hypertension markers and mediators before and after treatment with dapagliflozin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesUnited States
CollaboratorsKaleida Health
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 2015
Enrollment StartNov 2015
Primary CompletionMar 2018
Study CompletionNov 2018
TodayJul 2026
First PostedMay 5, 2015
Enrollment StartNov 1, 2015
Primary CompletionMar 1, 2018
Study CompletionNov 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 11.2 years ago
Interventions
dapagliflozindrug
SGLT-2 inhibitor for the treatment of type 2 diabetes
Placebodrug